tiprankstipranks
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
US Market
CAI
Caris Life Sciences, Inc.
RESEARCH TOOLSreports
Want to see CAI full AI Analyst Report?

Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

174 Followers
See the Price Targets and Ratings of:

CAI Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
6 Buy
3 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Caris
Life Sciences, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAI Stock 12 Month Forecast

Average Price Target

$26.29
▲(69.37% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc. in the last 3 months. The average price target is $26.29 with a high forecast of $33.00 and a low forecast of $21.00. The average price target represents a 69.37% change from the last price of $15.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","37":"$37","19.75":"$19.75","25.5":"$25.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.285714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,19.75,25.5,31.25,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.67,17.00307692307692,18.336153846153845,19.66923076923077,21.002307692307692,22.335384615384616,23.66846153846154,25.00153846153846,26.334615384615383,27.667692307692306,29.00076923076923,30.333846153846153,31.666923076923077,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.67,16.486593406593407,17.303186813186812,18.119780219780218,18.936373626373626,19.75296703296703,20.56956043956044,21.386153846153846,22.20274725274725,23.019340659340656,23.835934065934065,24.652527472527474,25.46912087912088,{"y":26.285714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.67,16.08,16.49,16.9,17.31,17.72,18.13,18.54,18.95,19.36,19.77,20.18,20.59,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.67,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$33.00Average Price Target$26.29Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on CAI
Mark Massaro
BTIG
BTIG
$32→$33
Buy
112.63%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: vTv Therapeutics (NASDAQ: VTVT), TripAdvisor (NASDAQ: TRIP) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Piper Sandler Analyst forecast on CAI
David Westenberg
Piper Sandler
Piper Sandler
$21
Hold
35.31%
Upside
Reiterated
08/06/26
Piper Sandler Keeps Their Hold Rating on Caris Life Sciences, Inc. (CAI)
Canaccord Genuity Analyst forecast on CAI
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$22
Hold
41.75%
Upside
Reiterated
08/06/26
Caris Life Sciences, Inc. (CAI) Receives a Hold from Canaccord Genuity
Evercore ISI Analyst forecast on CAI
Vijay Kumar
Evercore ISI
Evercore ISI
$25→$26
Buy
67.53%
Upside
Reiterated
08/06/26
Caris Life Sciences price target raised to $26 from $25 at Evercore ISICaris Life Sciences price target raised to $26 from $25 at Evercore ISI
Bank of America Securities Analyst forecast on CAI
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/06/26
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
J.P. Morgan Analyst forecast on CAI
Casey Woodring
J.P. Morgan
J.P. Morgan
$25
Buy
61.08%
Upside
Reiterated
08/06/26
Caris Life Sciences, Inc. (CAI) Receives a Buy from J.P. Morgan
TD Cowen Analyst forecast on CAI
Daniel Brennan
TD Cowen
TD Cowen
$31→$30
Buy
93.30%
Upside
Assigned
07/15/26
Caris Life Sciences price target lowered to $30 from $31 at TD CowenCaris Life Sciences price target lowered to $30 from $31 at TD Cowen
Goldman Sachs Analyst forecast on CAI
Evie Koslosky
Goldman Sachs
Goldman Sachs
$27
Buy
73.97%
Upside
Reiterated
07/01/26
Analyst Initiates Buy Rating on Caris, Highlighting Caris Detect Launch and Early Positive Economics
Wolfe Research Analyst forecast on CAI
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
06/01/26
Caris Life Sciences assumed at Peer Perform from Outperform at Wolfe ResearchCaris Life Sciences assumed at Peer Perform from Outperform at Wolfe Research
Guggenheim Analyst forecast on CAI
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$36
Buy
131.96%
Upside
Reiterated
05/11/26
Guggenheim Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)
Robert W. Baird Analyst forecast on CAI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$28→$22
Buy
41.75%
Upside
Reiterated
05/08/26
Caris Life Sciences price target lowered to $22 from $28 at BairdCaris Life Sciences price target lowered to $22 from $28 at Baird
Citi Analyst forecast on CAI
Patrick B Donnelly
Citi
Citi
$35→$28
Buy
80.41%
Upside
Reiterated
05/08/26
Caris Life Sciences price target lowered to $28 from $35 at CitiCaris Life Sciences price target lowered to $28 from $35 at Citi
Jefferies Analyst forecast on CAI
Tycho Peterson
Jefferies
Jefferies
$28
Buy
80.41%
Upside
Initiated
04/12/26
Caris Life Sciences initiated with a Buy at JefferiesCaris Life Sciences initiated with a Buy at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on CAI
Mark Massaro
BTIG
BTIG
$32→$33
Buy
112.63%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: vTv Therapeutics (NASDAQ: VTVT), TripAdvisor (NASDAQ: TRIP) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Piper Sandler Analyst forecast on CAI
David Westenberg
Piper Sandler
Piper Sandler
$21
Hold
35.31%
Upside
Reiterated
08/06/26
Piper Sandler Keeps Their Hold Rating on Caris Life Sciences, Inc. (CAI)
Canaccord Genuity Analyst forecast on CAI
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$22
Hold
41.75%
Upside
Reiterated
08/06/26
Caris Life Sciences, Inc. (CAI) Receives a Hold from Canaccord Genuity
Evercore ISI Analyst forecast on CAI
Vijay Kumar
Evercore ISI
Evercore ISI
$25→$26
Buy
67.53%
Upside
Reiterated
08/06/26
Caris Life Sciences price target raised to $26 from $25 at Evercore ISICaris Life Sciences price target raised to $26 from $25 at Evercore ISI
Bank of America Securities Analyst forecast on CAI
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/06/26
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
J.P. Morgan Analyst forecast on CAI
Casey Woodring
J.P. Morgan
J.P. Morgan
$25
Buy
61.08%
Upside
Reiterated
08/06/26
Caris Life Sciences, Inc. (CAI) Receives a Buy from J.P. Morgan
TD Cowen Analyst forecast on CAI
Daniel Brennan
TD Cowen
TD Cowen
$31→$30
Buy
93.30%
Upside
Assigned
07/15/26
Caris Life Sciences price target lowered to $30 from $31 at TD CowenCaris Life Sciences price target lowered to $30 from $31 at TD Cowen
Goldman Sachs Analyst forecast on CAI
Evie Koslosky
Goldman Sachs
Goldman Sachs
$27
Buy
73.97%
Upside
Reiterated
07/01/26
Analyst Initiates Buy Rating on Caris, Highlighting Caris Detect Launch and Early Positive Economics
Wolfe Research Analyst forecast on CAI
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
06/01/26
Caris Life Sciences assumed at Peer Perform from Outperform at Wolfe ResearchCaris Life Sciences assumed at Peer Perform from Outperform at Wolfe Research
Guggenheim Analyst forecast on CAI
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$36
Buy
131.96%
Upside
Reiterated
05/11/26
Guggenheim Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)
Robert W. Baird Analyst forecast on CAI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$28→$22
Buy
41.75%
Upside
Reiterated
05/08/26
Caris Life Sciences price target lowered to $22 from $28 at BairdCaris Life Sciences price target lowered to $22 from $28 at Baird
Citi Analyst forecast on CAI
Patrick B Donnelly
Citi
Citi
$35→$28
Buy
80.41%
Upside
Reiterated
05/08/26
Caris Life Sciences price target lowered to $28 from $35 at CitiCaris Life Sciences price target lowered to $28 from $35 at Citi
Jefferies Analyst forecast on CAI
Tycho Peterson
Jefferies
Jefferies
$28
Buy
80.41%
Upside
Initiated
04/12/26
Caris Life Sciences initiated with a Buy at JefferiesCaris Life Sciences initiated with a Buy at Jefferies
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caris Life Sciences, Inc.

3 Months
Michael RyskinBank of America Securities
Success Rate
4/8 ratings generated profit
50%
Average Return
-3.79%
Copying Michael Ryskin's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -3.79% per trade.
1 Year
Vijay KumarEvercore ISI
Success Rate
5/9 ratings generated profit
56%
Average Return
-2.33%
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -2.33% per trade.
2 Years
Vijay KumarEvercore ISI
Success Rate
5/9 ratings generated profit
56%
Average Return
-0.23%
Copying Vijay Kumar's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of -0.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAI Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
10
11
11
11
3
Buy
3
3
3
5
7
Hold
4
5
5
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
19
19
21
14
In the current month, CAI has received 10 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CAI average Analyst price target in the past 3 months is 26.29.
Each month's total comprises the sum of three months' worth of ratings.

CAI Financial Forecast

CAI Earnings Forecast

Next quarter’s earnings estimate for CAI is $0.03 with a range of $0.00 to $0.08. The previous quarter’s EPS was $0.00. CAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.
Next quarter’s earnings estimate for CAI is $0.03 with a range of $0.00 to $0.08. The previous quarter’s EPS was $0.00. CAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.

CAI Sales Forecast

Next quarter’s sales forecast for CAI is $255.50M with a range of $242.70M to $264.01M. The previous quarter’s sales results were $263.71M. CAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.
Next quarter’s sales forecast for CAI is $255.50M with a range of $242.70M to $264.01M. The previous quarter’s sales results were $263.71M. CAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.

CAI Stock Forecast FAQ

What is CAI’s average 12-month price target, according to analysts?
Based on analyst ratings, Caris Life Sciences, Inc.’s 12-month average price target is 26.29.
    What is CAI’s upside potential, based on the analysts’ average price target?
    Caris Life Sciences, Inc. has 69.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CAI a Buy, Sell or Hold?
          Caris Life Sciences, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Caris Life Sciences, Inc.’s price target?
            The average price target for Caris Life Sciences, Inc. is 26.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $33.00 ,the lowest forecast is $21.00. The average price target represents 69.37% Increase from the current price of $15.52.
              What do analysts say about Caris Life Sciences, Inc.?
              Caris Life Sciences, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of CAI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.